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The molecular pathogenesis underlying the primary myelofibrosis (PMF) progression to acute myeloid leukemia
(AML) is still not well defined. The involvement of microRNA (miRNA) is actually helping to shed light on an
important issue in the occurrence of myeloproliferative neoplasms (MPNs). However, the role of intronic miRNA,
derived from the intron regions of gene transcripts, has never been reported in MPNs. In this study, we describe a
PMF case evolved to AML with a t(12;18)(p13;q12) rearrangement showing the downregulation of the intronic
miR_4319 and the overexpression of its host gene, SET binding protein (SETBP1). A possible molecular mechanism
regulating the PMF progression to AML is discussed.
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Primary myelofibrosis (PMF) is a clonal stem cell
disorder currently classified as a myeloproliferative
neoplasm (MPN). The primary disease-causing mutation
in PMF is unknown. Janus kinase 2 (JAK2) gain of
function (JAK2V617F) and MPL gene mutation have
been described in approximately 50% and 5%–10% of
PMF patients, respectively [1]. Recently, the involvement
of microRNA (miRNA) has been reported in PMF, show-
ing a positive correlation with JAK2V617F allele burden
[2-4]. miRNA are a class of single-stranded noncoding
RNA that bind to the 3'-untranslated region of target
mRNA and suppress gene expression by translation re-
pression or mRNA degradation. About 37% of miRNA
appear to be located within introns of protein-coding
genes and may be transcribed by their own promoters
or by the host gene promoter with a correlated
expression [5]. Many miRNA target genes show* Correspondence: francesco.albano@uniba.it
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reproduction in any medium, provided the orexpression patterns that are significantly correlated
with the expression of the miRNA host genes [5].
We describe here a PMF case evolving to acute myeloid
leukemia (AML) with a t(12;18)(p13;q12) rearrangement,
showing SETBP1 overexpression and downregulation
of intronic miR_4319. The expression dysregulation
increased during PMF progression, suggesting the in-
volvement of a novel molecular mechanism in the
leukemogenesis.Case presentation
A 75-year-old man came to our attention in July 2008
with symptoms of anemia, leukocytosis, and splenomeg-
aly. Peripheral blood analysis showed leukoerythroblasto-
sis and a bone marrow biopsy revealed a megakaryocyte
proliferation with atypia, together with reticulin fibrosis.
Conventional cytogenetic analysis showed the following
karyotype: 46,XY[20]. Molecular analysis excluded the
presence of the 5'BCR/3'ABL transcript whereas
JAK2V617F was detected. In accordance with World
Health Organization (WHO) 2008 criteria, a diagnosis of
PMF was made. Treatment with hydroxyurea was started.
In August 2009, the patient showed a raised leukocytes
count. A bone marrow aspirate detected 30% of theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Cytogenetic analysis revealed the following karyotype: 46,
XY,t(12;18)(p13;q12)[20]. Molecular analysis demonstrated
the presence of the JAK2 wild-type gene. Treatment with
low dose ARA-C was started but the patient died a few
days later of disease progression.
Fluorescence in situ hybridization (FISH) analysis was
performed at the onset of the AML diagnosis using bac-
terial artificial chromosome (BAC) probes selected
according to the University of California Santa Cruz
(UCSC) database (http://genome.ucsc.edu/index.html;
February 2009 release). This analysis showed the occur-
rence of a t(12;18)(p13.2;q12.3) rearrangement with break-
points mapping inside ETV6 on chromosome 12 and
inside BCO51727 on chromosome 18 (Figure 1A, B).
Notably, the chromosome 12 breakpoint was mapped
between the BAC clones RP11-639O1 and RP11-418C2
(12p13.2), whereas the clones RP11-951D16 and RP11-
840B16 (18q12.3) delimited the breakpoint region on
chromosome 18 (Figure 1A). At the PMF onset, FISH
did not reveal the presence of the t(12;18) rearrangement.
Reverse transcription PCR (RT-PCR) experiments
performed to verify the occurrence of possible fusion
genes involving ETV6 and BCO51727 showed a 5'ETV6/
3'BCO51727 fusion transcript using primers mapping
inside ETV6 exon 1 (5'GGGAGAGATGCTGGAAGAA
ACT3') and BCO51727 exon 4 (5'AAGCCCAATGTTTFigure 1 FISH and molecular characterization of the t(12;18)(p13.2;q1
18 breakpoints identification in the follow-up sample (on the left). A schem
cytogenetic experiments is shown (on the right). (B) RT-PCR experiments s
BC051727 exon 3 (underlined). A truncated fusion protein was generated.CAAGACCTC3'). The 5'ETV6/3'BCO51727 fusion gene
was shown to be constituted by ETV6 exon 1 joined to
BCO51727 exons 3, 4, and 5 (Figure 1B).
This breakpoint was different from the one previously
reported, but a truncated protein was produced result-
ing from the presence of premature stop codons
(Figure 1B). No reciprocal 5'BCO51727/3'ETV6 fusion
transcript was detected (data not shown). As the t
(12;18) breakpoints were located about 300 kbp centro-
merically to SETBP1 (18q12.3), we analyzed the gene
expression by quantitative real-time PCR (qRT-PCR)
experiments. The β-glucuronidase (β-GUS) gene was
selected as an endogenous control and a pool of cDNA
derived from bone marrow cells of ten healthy indivi-
duals was used as calibrator. This analysis showed
SETBP1 overexpression by a mean factor of 1.54 and
2.88 in samples at the onset of PMF and at progression
to AML, respectively (Figure 2A).
The UCSC database was queried at the “sno/miRNA”
track to verify the presence of miRNA close to the t
(12;18) breakpoints; interestingly, miR_4319 mapped in-
side intron 4 of SETBP1. miRNA expression analysis was
performed by qRT-PCR with a specific primer pair, Hs
miR-4319 miScript Primer Assay, and RNU6B miScript
Primer Assay for normalization (Qiagen). qRT-PCR
experiments showed downregulation of miR_4319 by a
mean factor of 0.35 and 0.18 at PMF onset and2.3) rearrangement. (A) FISH analysis showing chromosome 12 and
atic representation of genes and BAC clones used in molecular
howing 5'ETV6/3'BCO51727 produced by the fusion of ETV6 exon 1 with
Figure 2 Results of qRT-PCR studies. Graphic representation of SETBP1 (A) and miR_4319 (B) expression detected in the onset and
follow-up samples of the analyzed patient and in normal bone marrow samples (NBM).
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of the MicroCosm (http://www.ebi.ac.uk/enright-srv/
microcosm/) and TargetScan (http://www.targetscan.
org/) databases did not elicit any predicted target genes
of miR_4319.
Conclusions
We report, for the first time, concomitant dysregulation
of SETBP1 and of its intronic miRNA in a PMF case
evolving to AML showing a t(12;18)(p13.2;q12.3) re-
arrangement. To date, SETBP1 overexpression has been
described as a recurrent molecular event in 27.6% of AML
patients at diagnosis, playing a crucial role in the leukemic
transformation through the protein phosphatase 2A inhib-
ition [6,7]. By contrast, the involvement of miR_4319 has
never been previously demonstrated in AML.It is known that intronic miRNA and host genes could
show a correlative or discordant expression [5]. Several
possible mechanisms could explain host-gene-independent
expression, such as different transcript stabilities, post-
transcriptional miRNA regulation, or the presence of a
specific miRNA promoter [5,8]. In our case, the unrelated
expression and opposite orientation between miR_4319
and SETBP1 suggest the existence of different, independent
promoters.
Moreover, the occurrence of SETBP1 and miR_4319
dysregulation in the sample at diagnosis suggests the pres-
ence of the leukemic clone at too low a level to be
detected by FISH. The disappearance during PMF pro-
gression of JAK2V617F at the same time as the leukemic
clone expansion suggests an outstanding pathogenetic role
for SETBP1 and miR_4319 in PMF evolution to AML.
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